Given the widespread use of the low-calorie sweetener aspartame over the last 30 years, the current work was undertaken to evaluate aspartame epidemiology studies looking at cancer endpoints against quality appraisal criteria. The quality appraisal tool used was from the National Heart, Lung and Blood Institute (NHLBI) of the National Institute of Health. Studies identified included nine case-control studies and five prospective cohort studies. Most studies assessed low-calorie or diet beverages rather than aspartame intake specifically; however, common use of aspartame in diet sodas does allow for some general extrapolation of results. Following consideration of study quality, two case-control and five prospective studies were considered to meet the majority of the NHLBI criteria. The primary limitation of the other case-control studies was an inadequate sample size. Overall, the results of the studies do not support that exposures to low and no-calorie sweeteners and beverages, and by extension aspartame, are associated with an increased risk of cancer in humans.
Introduction
Aspartame, or N-(L-α-Aspartyl)-L-phenylalanine, 1-methyl ester, is a low-calorie sweetener, with the same caloric intake as sugar, 4 kcal/g, but it is approximately 200 times sweeter and thus it is used in foods and beverages in very low amounts, resulting in low-calorie intake. It is synthesized from the two amino acids phenylalanine and aspartic acid. A detailed description of the manufacturing process of aspartame is described elsewhere (Butchko et al., 2002; Magnuson et al., 2007) . Once ingested, aspartame is hydrolyzed in the gut to the amino acids, aspartic acid and phenylalanine, with low amounts of methanol (lower than normal daily endogenous production), all of which are metabolized via normal well-characterized endogenous metabolic pathways (Magnuson et al., 2007; EFSA, 2013) . The structure for aspartame is provided in Fig. 1 .
Aspartame can be used as a table top sweetener and in beverages and a wide variety of prepared foods that do not require heating during preparation, such as cereals, dairy products, chewing gum, packaged desserts, sauces, and syrups. In the United States (U.S.), a final decision from the Food and Drug Administration (FDA) approving aspartame for use in foods was issued in 1981 with the provisos that foods be labelled as contains phenylalanine (for individuals afflicted with phenylketonuria, or PKU) and for aspartame not to be used for cooking or baking (46 FR 38283) (U.S. FDA, 1981) . Individuals diagnosed with PKU monitor dietary phenylalanine regardless of its source. Aspartame has now been approved for use in over 90 countries (Magnuson et al., 2007) .
Aspartame, which has now been a component of the diet for over 30 years, has been included in a number of epidemiology studies investigating various cancer endpoints, including brain, urinary tract, pancreatic, endometrial cancers, and lymphoma and leukemias. Bernardo et al. (2016) conducted a systematic review of studies that evaluated adverse effects in adult and child consumers of low and nocalorie (L&NC) sweeteners, compared with individuals who were not consumers. For this assessment, Bernardo et al. (2016) chose the Castle Ottawa Scale and Oxford classification to critically evaluate the studies. From their analysis of the available studies, they concluded that there was no association between aspartame consumption and increased risk of cancers of the brain, or hematopoietic, digestive, and reproductive systems, or between L&NC sweeteners consumption, in general, and the risk of cancers of the kidney or bladder.
The Castle Ottawa Scale and Oxford classification is only one of several quality appraisal tools available. Other quality appraisal tools that allow for the evaluation of case-control and cohort epidemiology studies are available from the National Heart, Lung and Blood Institute (NHLBI) of the National Institute of Health (NHLBI, 2014a,b) , the Critical Appraisal Skills Programme (CASP, 2017a,b) , and the Academy of Nutrition and Dietetics (2016) (GRADE method) quality appraisal tools for hazard and risk assessment is the up-front focus on the methodology of published research.
The objective of the current research was to conduct a comprehensive analysis of the available epidemiology studies of aspartame using the National Institute of Health quality appraisal tool to assess study quality. The findings determined from the most robust studies will be reviewed in assessing potential carcinogenic risks of aspartame consumption and compared to results of studies which were assessed using the Castle Ottawa Scale and Oxford classification.
Methodology

Literature searches
All cancer epidemiology studies included in the Bernardo et al. (2016) E 951; 22839-47-0) combined with epidemiology terms (human; humans; subject; subjects; patient*; clinical*; volunteer*; men; women; male; female; double blind*; single blind*; open label*; cross over; crossover; cohort; randomiz*; randomis*; placebo control*). The asterisk denotes truncation. The literature search also was restricted to studies that were conducted via the oral route for humans (oral*; diet; dietary; ingest*; capsule; tablet; supplement*; consum*; provid*; administ*). No restrictions with respect to language or year of publication were imposed for the literature search, although studies for which the exposure timeframe predated the approval of aspartame were not obtained. All abstracts that included the above search terms in any fields were selected and screened. In addition to the electronic searches, publications that were reviews, commentaries, editorials, or similar types of publications were obtained and the reference lists were hand-searched to further ensure that all original epidemiology studies were identified.
In total, over 40 publications were obtained and pre-screened to ensure that the research studies were conducted in humans and were epidemiology studies (e.g. case-control, cohort, cross-sectional). Studies conducted in animals were excluded from this assessment but have been evaluated separately in another publication. Also, publications that presented reviews and/or summaries of other published primary literature were excluded so long as the primary study was available for evaluation.
Quality appraisal tools
Demonstrating a causal relationship between exposure to a chemical agent and carcinogenicity on the basis of human data is complicated by the long latency period for cancer, estimates of exposure that may be imprecise if based on recollection or obtained by proxy, other concurrent chemical exposures (e.g. other L&NC sweeteners, dietary exposures to other additives), as well as general confounding factors associated with subjects' lifestyles and other environmental factors. The criteria included in the appraisal tools aid in the identification of the studies that were conducted according to a suitable study design and, by extension, are most reliable for use in hazard and risk assessment.
Quality appraisal tools that allow for the evaluation of case-control and cohort epidemiology studies are available from the NHLBI of the National Institute of Health (NHLBI, 2014a,b) , the Critical Appraisal Skills Programme tools (CASP, 2017a,b) , and the Academy of Nutrition and Dietetics (2016) (GRADE method). Many of the other tools available are suitable for the evaluation of clinical trials conducted for medical intervention or similar research purposes under controlled conditions. These latter tools are not relevant to the current investigation as no such clinical trials were identified for aspartame.
For the current assessment, the NHLBI tool, which requires at least two independent evaluators, was selected; however, the assessment criteria were fairly comparable between the three quality assessment methods. All three tools focused attention on the recruitment of subjects, methods of data collection, and data analysis with respect to validity of the study.
The NHLBI appraisal tools for the quality assessment of case-control studies and observational cohort and cross-sectional studies were used in this assessment. The criteria are detailed in Table 1 .
Results
Epidemiology studies
Overview
In total, 42 publications that appeared to address, in some respect, the carcinogenic potential of aspartame to humans were obtained from the electronic and manual searches. Approximately 33 were identified from the electronic searches, with an additional nine identified from the manual search. These included the seven epidemiology studies discussed in Bernardo et al. (2016) . Studies that alluded to the carcinogenicity of L&NC sweeteners or diet beverages, in general, also were obtained. The vast majority of the publications identified were review papers or short communications (commentaries, editorials, letters to editor, abstracts) as opposed to original research with detailed descriptions of the methodologies employed, assessment of bias and confounding factors, and nature of subjects included in the study. In many studies indicated to be investigations of the potential carcinogenic risks of aspartame, the exposures were instead based on consumption of diet beverages and/or L&NC sweetener packets rather than aspartame. While the results may be confounded by previous, concomitant, or later exposures to other L&NC sweeteners, as this limitation applied to the majority of the studies available, these studies were not excluded on this basis alone. Furthermore, the common use of aspartame in diet sodas does allow for some assurance that the results obtained are generally applicable.
Abbreviations
The publications determined to be reports of original epidemiology studies are listed in Table 2 . These included one ecological study, nine case-control studies, and five prospective cohort studies.
Ecological studies
Ecological studies attempt to correlate an increase in the incidence of cancer in a general population (often using a cancer database) to some exposure event that appears to also be increasing. Such studies are possibly useful for hypothesis generating, but cannot in itself prove causation.
In the ecological study identified, Olney et al. (1996) mined data on brain cancer incidence collected under the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) Program. Olney et al. (1996) obtained data from 1975 to 1992 on cases of brain cancer and associated tissues (meninges, spinal cord, cranial nerves, miscellaneous central nervous systems) with morphological types including astrocytomas, anaplastic astrocytoma, pilocytic astrocytoma, glioblastomas, gliomas, oligodendrogliomas, medulloblastomas, primitive neuroectodermal tumors, and ependymomas. The incidence rates collected from 1975 to 1992 were age-adjusted using population information provided in SEER and also the 1970 U.S. standard population. The incidence data, for all brain tumors combined, were graphed and noted by the authors to present a biphasic curve with a sharp increase in the mid-1980s. The mean annual incidence of all brain tumors combined was reported to be 47.89 tumors per million people for the period from 1975 and 1984 and 53.26 tumors per million people for the period from 1985 to 1992. Olney et al. (1996) concluded that aspartame was a promising candidate for explaining the apparent surge in brain tumors in the mid-1980s; however, other than noting that aspartame had been on the market for about 3 years before the surge, and that people drink a lot of coffee, tea, and diet soft drinks, no attempt to verify that aspartame was consumed, nor to quantify aspartame intakes, was made (although an absence of exposure data is consistent with ecological studies). It is noteworthy that while people do drink a lot of beverages, there are many other beverage choices in addition to those sweetened with non-caloric sweeteners.
Case-control studies
Nine case-control studies conducted in several different countries and for a wide variety of cancers were identified ( Table 2 ). The identified studies are discussed below in chronological order of publication.
The first of the case-control studies, Ewertz and Gill (1990) , was considered to have clearly defined the objective of their research, which was to evaluate the potential impact of various dietary factors on the risk of breast cancer in 1474 women, diagnosed in Denmark between 1983 and 1984, compared to 1322 control participants (age-stratified random participants from the general population). Special focus was given to food sources of dietary fat and beta-carotene, but the intake of sugar and artificial sweeteners added to tea or coffee also was included in the evaluation. However, aspartame was not mentioned in the study, and the authors stated that the artificial sweeteners were mainly saccharin and cyclamate. Furthermore, the cases were diagnosed in 1983 and 1984, which was only 2-3 years after aspartame was first approved in the U.S. Given these reasons, it was determined that the results of this study would not provide any reliable information on the potential (continued on next page) L. Haighton, et al. Regulatory Toxicology and Pharmacology 103 (2019) 352-362 L. Haighton, et al. Regulatory Toxicology and Pharmacology 103 (2019) 352-362 effects of aspartame, and it was not considered further. Gurney et al. (1997) conducted a case-control study with a small number of pediatric brain cancer patients. The patients, who were 19 years of age or younger and diagnosed with a brain tumor between 1984 and 1991 in the U.S., were part of a population-based case-control study of numerous environmental and nutritional risk factors to which aspartame was added to the questionnaire midway through the study. Information on aspartame consumption prior to diagnosis for 56 case patients, and comparable reference data for the 94 control subjects, was collected from the biologic mothers through an in-person interview. It was unclear if the assessors were blinded. The controls were recruited randomly by phone and were matched by age at diagnosis, birth, gender, and study location (Los Angeles and San Francisco for aspartame evaluation). The subjects included were all born in 1981, the year aspartame was approved, or later. For a subset of the group, 49 cases and 90 controls, the mother's intake of aspartame during pregnancy and breast-feeding also was evaluated. Odds ratios (ORs) and confidence intervals (CIs) were determined using unconditional logistic regression with adjustment for frequency-matched variables (study site, sex, age at diagnosis or reference date, and birth year), as well as maternal vitamin use, cured meat consumption, passive smoke exposure, x-ray exposure, head injury, and family history of brain cancer. No increases in brain cancer risk were observed with patient consumption of aspartame (adjusted OR 1.1, CI 0.5-2.6 and OR 0.9, CI 0.3-2.4 for all sources and diet drinks, respectively) or maternal consumption of aspartame (adjusted OR 0.7, CI 0.3-1.7 and OR 0.9, CI 0.3-2.8) for all sources and diet drinks, respectively) or any other data breakdowns, which included age at first consumption, number of years of consumption, or frequency of consumption, or with individual tumor types. With respect to the NHLBI criteria, while the answer to most questions was "yes", the authors did not present a sample size justification but did note that the sample size was small and the CIs were wide. Also, no information on inclusion and exclusion criteria was provided in the publication and it was not reported if the assessors were blinded to the status of the participants. The authors did adjust for certain known or suspect risk factors for brain cancer (maternal vitamin use, cured meat consumption, passive smoke exposure, x-ray exposure, head injury, and family history of brain cancer). The results of this study did not support that aspartame was associated with an increased risk of childhood brain tumors; however, it is questionable if such an association could be adequately ruled out given the small number of cases. Hardell et al. (2001) conducted a case-control study investigating brain tumor risk which considered exposures to numerous agents, products (e.g. x-rays, cellphones), as well as occupational exposures. The study was conducted in Sweden with adult patients (20-80 years of age; 1994 to 1996), using 233 cases and 425 controls. The aspartame analysis was based on 30 cases and 45 controls. No sample size justification was included, and the authors increased the sample size to include benign tumors (Hardell et al., 2001) . The controls were recruited via the population register and matched by sex, age, and location. Tabular results were presented as aspartame; however, exposure information collected was for low-calorie drinks rather than aspartame, with the authors noting that "most low-calorie drinks contain aspartame". Other sources of aspartame were not included. Exposure information was obtained by telephone interview using a written protocol, and it was noted that questionnaires were blinded as to whether they were for cases or controls. Users of low-calorie drinks were asked about duration of use, frequency of consumption, and amounts consumed, although it is unclear what parameter the results were based on. Data were analyzed using conditional logistic regression. Adjustment for confounders was not indicated. Consumption of low-calorie drinks (taken as aspartame) and risks of benign or malignant tumors were not statistically significant (benign: OR 0.96, CI 0.36-2.54; malignant: 1.70, CI 0.84-3.44; total OR 1.24, CI 0.72-2.14); however, the authors concluded there to be a "non-significantly increased" risk for low-calorie drink consumption and malignant brain tumors. The authors did not adjust for any confounding variables. Given the small number of cases, it is questionable whether this study could rule out an association between aspartame consumption and cancer risk.
An association between maternal dietary intakes and the risk of brain tumors (medulloblastoma and primitive neuroectodermal tumors) in their children was investigated by Bunin et al. (2005) . A total of 315 patients under age six at diagnosis, from 1991 to 1997, registered in the U.S. with the Children's Cancer Group were included. The mothers of these patients were matched with 315 controls. The mothers were interviewed by telephone to obtain information on their diet in the year before pregnancy (used to estimate early pregnancy exposures -periconception) and during the second trimester (mid-pregnancy). Data were analyzed by unconditional logistic regression using indicator variables, and with adjustments for income level, race, age of child, date of interview, maternal weight gain, smoking, and total calories. Analysis of diet soda was also adjusted for regular soda intake. The crude analysis indicated an increasing trend with diet soda consumption at preconception (OR 1.6, CI 1.0, 2.3 for ≥2 drinks/ day), but not when adjusted for confounders (OR 1.3, CI 0.8-2.4 for ≥2 drinks/day compared to < 1/month), nor at the mid-pregnancy period for crude (OR 1.2, CI 0.7-2.0 for ≥2 drinks/day compared to < 1/month) or adjusted results (OR 1.3, CI 0.8-2.3 for ≥2 drinks/day compared to < 1/ month). Thus, it was concluded by the authors that the results did not support an increased risk of brain cancer with aspartame. The results for diet soda were considered to be representative of aspartame, as the authors noted that it was the most-used L&NC sweetener in diet drinks during the time the patients were in utero. The authors did not include a sample size justification but noted that future investigations should include "similar (or larger)" sample sizes. It was not reported if the assessors were blinded. The authors were concluded to have met all of the other NHLBI criteria. Gallus et al. (2007) reported the results from an integrated network of case-control studies in patients with various cancers which investigated the potential role of L&NC sweeteners. The study, which was conducted with patients in Italy between 1991 and 2004, included patients with the following cancers: oral cavity/pharynx (n = 598), larynx (n = 460), esophagus (n = 304), colon (n = 1225), rectum (n = 728), breast (n = 2569), ovary (n = 1031), prostate (n = 1294), and kidney/renal cell carcinoma (n = 767). The controls were patients from the same hospitals that had nonneoplastic conditions such as traumas, orthopedic problems, and acute surgical disorders (n = 7028; 3301 men and 3727 women, of which 4838 were in more than one study). Details of the selection process, particularly of the cases were not clearly stated. Subjects were interviewed during their hospital admission, using a food frequency questionnaire, about their weekly consumption of sugar (as teaspoons), or saccharin, and "other" sweeteners (as sachets or tablets) over the previous 2 years. The researchers noted that the other sweeteners were "mainly aspartame". It is noted that information on diet soft drinks consumption was not collected, although the authors stated that the use of such products was recent in Italy. Data were analyzed for saccharin, other sweeteners, and all sweeteners. The ORs and 95% CIs were determined using unconditional multiple logistic regression adjusting for age, sex, study center, education, body mass index (BMI), energy intake, and lifestyle factors (alcohol, smoking, hot beverage consumption). Aspartame was grouped with the "other sweeteners" for which the number of cases and controls that consumed greater than 0 sachets or tablets/day was a much smaller subset: oral cavity/pharynx (12 cases; 86 controls; OR 0.77, CI 0.39-1.53), larynx (21 cases; 55 controls; OR 1.62, CI 0.84-3.14), esophagus (10 cases; 40 controls; OR 0.77, CI 0.34-1.75), colon (88 cases; 327 controls; OR 0.90, CI 0.70-1.16), rectum (39 cases; 327 controls; OR 0.71, CI 0.50-1.02), breast (219 cases; 270 controls; OR 0.80, CI 0.65-0.97), ovary (73 cases; 236 controls; OR 0.75, CI 0.56-1.00), prostate (77 cases: 68 controls; OR 1.23, CI 0.86-1.76), kidney/renal cell carcinoma (57 cases; 109 control; OR 1.03, CI 0.73-1.46). The results of the study do not support an association between an increased risk of any of the cancers with consumption of saccharin or other sweeteners, noted to be mainly aspartame, as sachets or tablets. The authors did not include a sample size justification and although the number of cases/controls was large, statistical power was limited by low rates of sweetener consumption and the degree of stratification of exposure, confounding variables, and histological type of cancer involved. It was also unclear if the cases or controls were randomly selected from those eligible, since the number of potential cases was not reported and the details of case selection were limited. It was not reported if the assessors were blind to the status of the participants; however, it is unlikely since controls were recruited from hospital admissions for non-neoplastic conditions.
The risk of urinary tract tumors (UTT) from consumption of common L& NC sweeteners was investigated in a case-control study of patients in Cordoba, Argentina admitted from 1999 to 2006 (Andreatta et al., 2008a) . Hospital patients with UTT of transitional-cell types from renal pelvises, ureters, and/or bladder (n = 197) were matched with controls (n = 397) who were patients admitted to the same hospitals with acute, non-neoplastic and non-urinary tract conditions (osteoarticular, routine check-ups, injuries, cardiovascular and respiratory diseases, etc.). Subjects were interviewed using a food frequency questionnaire and asked to estimate intakes over the previous 5 years. Patients who used L&NC sweeteners were asked about the brand, which was noted to be saccharin/cyclamate or aspartame/ acesulfame-K. Only L&NC sweeteners as added to tea, coffee, or mate beverages ("infusions") were included. No information on diet beverages or other dietetic foods were considered. Multiple logistic regression models were used to determine crude, stratified, and Mantel-Haenszel adjusted OR and 95% CI. Adjustments were made for age, sex, BMI, social status, tobacco uses. The majority of respondents did not report using L&NC sweeteners. The number of cases that used aspartame/acesulfame-K was 11 compared to 16 controls. Saccharin/cyclamate was slightly higher at 40 cases versus 71 controls. For the assessment of years of L&NC sweetener consumption, determined to be 1-9 years for short-term consumption, and greater or equal to 10 years for long-term, the aspartame/acesulfame-K and saccharin/cyclamate users were combined: short-term -21 cases versus 55 controls; longterm 30 cases versus 32 controls. Separate analyses were not conducted for aspartame alone or with acesulfame-K. All results were presented for the sweeteners combined of which 80% was saccharin and/or cyclamate. Based on the tabulated results, L&NC sweeteners combined were not associated with an increased risk of UTT when "ever" users were compared to "never" users defined as ≥1 years, and 0 years of use, respectively. No association was found for short-term (1-9 years) use and risk of UTT, while a positive association with risk of UTT was reported for long-term (≥10 years) use of L&NC sweeteners. A total of 11 cases were users of aspartame (or acesulfame-K), for short and long-term combined. The number of long-term users of aspartame was not reported. No sample size justification was provided, it was unclear if the assessors were blinded (although the study design would suggest that this was not the case), it is unclear if the cases and controls were randomly selected from those eligible. Exposure was established on the basis of a food frequency questionnaire regarding the previous 5 years' dietary habits and exposure related to years of potential aspartame consumption; however, there was quantification of the amount ingested. Overall the utility of this study for assessing cancer risks associated with aspartame consumption is greatly limited by the small number of cases and incomplete exposure data. Bosetti et al. (2009) presented the results of an updated case-control study of cancer patients in Italy conducted to assess L&NC sweetener consumption and the risks of gastric, pancreatic, and endometrial cancers, which were not previously assessed in Gallus et al. (2007) . Cancer patients and controls with acute non-neoplastic disorders were recruited from the same three hospitals in Italy between 1991 and 2007. Methodological details are as discussed above for the previous case-control study conducted in Italy. As before, aspartame was grouped with the "other sweeteners" for which the number of cases and controls that consumed greater than 0 sachets or tablets/day was a much smaller subset: stomach (17 cases; 51 controls; OR 0.86, CI 0.45-1.67), pancreatic (35 cases; 49 controls; OR 1.1, CI 0.66-2.04), endometrial (58 cases; 87 controls; OR 1.07, CI 0.71-1.16). As with the previous study, the results did not support an association between the consumption of L&NC sweeteners and the risks of stomach, pancreatic or endometrial cancers. With respect to the NHLBI questions, the same issues noted with Gallus et al. (2007) apply to this study, although the authors noted that they thought it unlikely that a larger sample size would have resulted in statistically significant positive associations. Chan et al. (2009) conducted a population based case-control study to investigate a link between consumption of sweets and sweetened beverages and pancreatic cancers. Aspartame was not specifically mentioned; however, low-calorie, or non-caloric beverages, which would include diet soft drinks, teas and coffee, were included as a comparison to sweetened beverages. Sweets, sugar, and sugary beverages were hypothesized to be associated with an increased pancreatic cancer risk possibly related to hyperglycemia and hyperinsulinemia. Cancer cases from San Francisco were identified via the Northern California Cancer Center between 1995 and 1999. Controls (n = 1701) were obtained using random digit dial. In-person interviews were conducted to determine food frequency. All cases (n = 532) were still alive, thus no proxy interviews were conducted. Beverage categories assessed which could conceivably be expected to contain L&NC sweeteners such as aspartame included "sugar-free carbonated beverages", "low calorie cola", "low calorie caffeine-free cola", "other low calorie carbonated beverages". Intakes (1 serving = 1 can, glass, bottle, or cup) were assessed as < 1/month, 1 to 3/month, 1 to 6/week, ≥1/day. Results were adjusted for age, sex, calories, BMI, race, education, smoking, history of diabetes, and physical activity. Unconditional logistic regression was used to calculate relative risk (RR) and the Wald procedure used for linear trend test. Some but not all low-calorie carbonated drinks were linked with a 50-80% increased risk of pancreatic cancer, for high frequency users (≥1 drink/day) compared to < 1/month, and were statistically significant in males only (sugar-free carbonated beverages: OR 1.8, CI 1.1-2.8; low calorie cola: OR 1.8, CI 1.1-2.9; low calorie caffeine-free cola: OR 1.1, CI 0.5-2.5; other low calorie carbonated beverages: OR 1.8, CI 0.8-3.8). However, the number of cases who were high frequency users of these beverages was quite low (n = 21 to 57, depending on category and presented as men plus women). Beverages with added L&NC sweeteners (e.g. tea, coffee) were not associated with an increased pancreatic cancer risk (OR 1.3, CI 0.8-1.9) (information was reported but not tabulated). Whether the assessors were blinded to the status of cases and controls was not reported but is unlikely given the study design. Sample size justification was not specifically stated, although the authors considered that the large sample size was a strength of the study. The authors were considered to have met the other NHLBI criteria.
A final case-control study identified was a pilot study conducted in France in which Cabaniols et al. (2011) intended to investigate the association between psychological stress and personal habits and cancer risk. The authors identified 122 adult patients (72 males and 50 females) who had been newly diagnosed with malignant primitive brain tumors (MPBT) between January and December 2005. These cases were age and gender matched to 122 control subjects, all of whom received in-depth surveys related to medical history, dietary intake habits, and other health status issues, such as smoking, stress, sleep patterns, accounting for the 5 years prior to diagnosis. Aspartame intake was queried only as " < 1 per week" which accounted for "non-consumers" or "≥1 per week", which were considered by investigators to be "regular consumers". The "regular" intake of aspartame was not associated with an increased risk of MPBT (OR 1.02, CI 0.57-1.85). The sources of aspartame were not clarified in the publication. The authors did not include a sample size justification but did note that due to the low sample size that results should be viewed cautiously. The authors did not blind the assessors and noted this to be a limitation of their study and it is unclear whether both cases and controls were interviewed in person.
While all of the case-control studies met many of the NHLBI criteria, only Bunin et al. (2005) and Chan et al. (2009) were considered to have a large enough sample size for reasonably concluding any association between aspartame consumption and cancer risk.
Prospective cohort studies
Five prospective studies were identified, which included consideration of aspartame or diet soda consumption (Table 2) . These are discussed below in chronological order of publication. Schernhammer et al. (2005) investigated the association between soft drink consumption and risk of pancreatic cancer using data from the Nurses' Health Study (NHS) (consisting of 88,794 females aged 30-55 years) and the Health Professionals Follow-up Study (HPFS) (consisting of 51,529 males aged 40 to 75), which took place between 1980 and 1998 (NHS) and 1986 to 1998 (HPFS). Soft drink consumption was measured based on participant responses to the food frequency questionnaire that were sent at baseline and every 4 years thereafter. The smoking status/history, BMI, incidence of diabetes, and physical activity of subjects was also tracked. Over the course of the study, 205 women and 174 men were diagnosed with pancreatic cancer. The investigators reported that the intake of diet soft drinks (< 1/month, 1 to 12/month, or > 3/week) was not associated with an increased risk of pancreatic cancer in either cohort or when data were combined. With all diet soft drinks combined, the RR was 1.02, (CI 0.79-1.32) for comparison of > 3 drinks/week versus < 1/month when adjusted (multivariate-adjusted for age, gender, follow-up cycle, history of diabetes, smoking status, caloric intake, non-vigorous, physical activity, other soft drinks, and BMI). With respect to NHLBI criteria, the main focus of the study was on sugar sweetened soft drinks; assessment of sugar free alternatives was a secondary objective and was not included in the hypothesis statement. No sample size justification, power description, or variance and effect estimates were provided, although the cohort study is recognized as one of the largest available. It was not reported if the assessors were blinded to the status of the participants. Loss to follow up after baseline was greater than 20% for females (∼28%) but it was still a very large cohort. Lim et al. (2006a,b) conducted a prospective study involving older adults (50-71 years of age at the start of the study) to determine if there was an association between aspartame consumption and the risks of hematopoietic cancer or brain cancer. The study followed 285,079 men and 188,905 women who were part of the National Institute of Health American Association of Retired Persons Diet and Health Study (NIH-AARP) Diet and Health Study Cohort, for 5 years (1995) (1996) (1997) (1998) (1999) (2000) . It should be noted that following an older cohort likely misses potential exposures to carcinogens earlier in life. Baseline intakes were assessed from a self-administered food frequency questionnaire that was mailed to participants living in eight areas of the U.S., which included questions on consumption of diet drinks (soda, fruit drinks, and iced tea) and use of L&NC sweeteners in hot drinks (coffee, tea). Exposure was assessed only once over the course of the study. It was assumed that the L&NC sweetener in each of the beverages was aspartame. While aspartame was noted to be the most common sweetener used in beverages for most of the 1980s and 1990s, other sweeteners in use could have included saccharin, acesulfame-K, sucralose, and, given the age of the cohort, cyclamate. Over the follow-up period, histologically confirmed cases of hematopoietic cancer and malignant gliomas were determined in 1888 and 315 respondents, respectively. Multivariable-adjusted RR and 95% CI adjusted for age, gender, race, BMI, and for history of diabetes were calculated using Cox proportional hazards regression. Consumption of beverages containing L&NC sweetener (assumed to be aspartame) was not associated with an increased risk in overall hematopoietic, its subtypes (Hodgkin's lymphoma, multiple myeloma, lymphoid malignancies, non-Hodgkin's lymphoma [NHL] , immunoblastic lymphoma, lymphoblastic lymphoma/leukemia, non-lymphoid leukemia) or brain cancer (all hematopoietic cancer [male + female] RR 0.98, CI 0.76-1.27; gliomas [male + female] RR 0.73, CI 0.46-1.15, for highest consumption versus none). The participation rate was not 50%; however, baseline was 3.5 million and of forms returned > 500,000 were filled out correctly. The timeframe was only 5 years but the subjects were older at baseline. Bao et al. (2008) evaluated 487,922 eligible participants from the NIH-AARP Diet and Health Study (284,076 men and 203,846 women; aged 50-71 years) to investigate the association between primarily sugar and added sugar intake and the incidence of pancreatic cancer, although the association with regular and diet soda intake was also measured. This was the same cohort as that used by Lim et al. (2006b) , and exposure was assessed only once. The consumption of added sugar and sugar-sweetened food, as well as regular and diet sodas, were estimated based on food frequency questionnaires. The participants were stratified into quintiles for dietary intake levels for the relevant food categories and in relation to diet soda intake, the quintiles corresponded to 0 g/day, 16.2 g/day, 74.8 g/day, 260.6 g/day, and 816.9 g/ day. During the mean follow up of 7.2 years, the investigators identified 1258 cases of pancreatic cancer amongst the participants. The investigators reported that there was no statistically significant association, as RR, between intake of diet soft drinks and the incidence of pancreatic cancer in men or women (or both) for any intake quintile, even when controlling for BMI, physical activity levels, and smoking status of the participants. The results for the comparison of the highest quintile versus none was a RR of 1.11 and CI 0.86-1.44 (Bao et al., 2008) . With respect to the NHLBI criteria, the same issues with Lim et al. (2006b) also applied to Bao et al. (2008) .
The risk of hematopoietic cancers from consumption of L&NC sweetened beverages also was investigated in a prospective cohort study by Schernhammer et al. (2012) . Two cohorts, the NHS and the HPFS, which included 77,218 females (30-55 years of age starting in 1976) and 47,810 men (40-75 years of age starting in 1986), respectively, were followed for over 22 years, during which 1324 cases of NHL, 285 cases of multiple myelomas, and 339 cases of leukemia were identified. Consumption was assessed at baseline using a mailed food frequency questionnaire. Soda consumption (diet and sugar containing) was assessed in 1984 for the NHS cohort and again in 1986 for both cohorts and every 4 years thereafter. Beverages that may have contained aspartame which were captured by the food frequency questionnaire included diet cola without caffeine, diet cola with caffeine, and other diet soda, as well as use of packets of NutraSweet and Equal (added in 1994) for use in hot beverages. Cox proportional hazards models were used to calculate multivariable RR and 95% CI comparing intakes for the highest and lowest consumers, and adjusting for age, BMI, smoking, physical activity, multivitamin use, questionnaire cycle, total energy intake, and for intakes of animal protein, alcohol, saturated fat, and fruits and vegetables. RRs for diet soda consumption over the full period (1984 -2006 for NHS and 1986 to 2006 and RRs for aspartame consumption from 1994 (when information on packets of L&NC sweeteners was added to the food frequency questionnaire) to 2006 were calculated. Data were analyzed for five categories of diet soda consumption (none; < 1 serving/week; 1-3.9 servings/week; 4-6.9 servings/week; ≥1 serving/day). No increased risks of NHL and multiple myeloma for combined cohorts (men and women) or for women alone were found. In men alone, an increased risk of NHL (RR 1.31, CI 1.01-1.72) and for subtypes, and multiple myeloma (RR 2.02, CI 1.20-3.40) was observed with ≥1 diet soda/day (the highest exposure group) compared to non-users. Lower consumption patterns (4-6.9 servings/week or less) were not associated with an increased risk of cancer. Higher consumption of regular, sugar sweetened beverages was also associated with a higher risk of NHL in men (RR 1.66, CI 1.10-2.51). An increased risk of leukemia with diet soda consumption was observed for men and women combined (RR 1.42, CI 1.0-2.02) for highest intake but not for each cohort individually. Similar results were observed with aspartame (increased risks for men but not women). The results were ambiguous with the authors concluding that their findings "preserved" the possibility of a detrimental association; however, the authors also stated that the inconsistency of the gender effects and apparent cancer risk association with regular sweetened (sugar) soda did not rule out chance as an explanation. Exposure was assessed more than once over time but with reduced statistical power. It was not reported if the assessors were blind to the status of the participants and loss to follow up was not clearly stated or discussed.
Using the CPS-II Nutrition Cohort, McCullough et al. (2014) identified 100,442 eligible subjects (43,350 men and 57,092 women; 47-95 years of age; median age of 69.0 years) to investigate the association between L&NC and sugar-sweetened carbonated beverage intake and risk of NHL during the period between 1999 and 2009. Within this cohort, the investigators identified 1196 cases of lymphoid neoplasms. Beverage intakes were assessed with modified Willett Food Frequency Questionnaires in 1999 and updated in 2003 (stratified into one of five intake categories). Total aspartame intake was calculated based on the assumption that all L&NC sweetened beverages were sweetened with aspartame at the following levels: 180 mg aspartame/355 mL (1 serving) of low-calorie cola with caffeine, 90 mg/355 mL of other lowcalorie soda with caffeine, and 70 mg/355 mL of other low-calorie soda without caffeine. The use of "NutraSweet or Equal" table-top sweeteners (20 mg aspartame/packet) was also surveyed. Investigators controlled for smoking status, BMI, history of diabetes, and energy intake as covariates. At baseline, men and women in the cohort consumed a mean (10th to 90 th percentile) of 795 mL (0-2.49 L) of L&NC sweetened carbonated beverages/week, which amounted to a reported mean aspartame intake of 46.6 (0-144) mg/day, and a median intake of 10 mg/ day. The investigators reported that the consumption of L&NC sweetened beverages was not associated with an increased risk of overall NHL nor with any major subtypes. The intake of aspartame was not associated with increased risk of NHL overall; however, the RR for diffuse large B-cell lymphoma was statistically significantly higher in Quintiles 2 and 3, but not at higher levels of intake and there was no trend (P = 0.51). Compared with non-consumers, the RR for NHL in occasional consumers of L&NC sweetened carbonated beverages (> 0 but < 1.78 L or > 0 to < 5 cans/week) was 1.15 (95% CI: 0.90-1.46), and for high-intake consumers (> 1.78 L/week) the RR was 0.84 (95% CI: 0.61-1.16). There were statistically significant, as well as insignificant, inverse trends reported by investigators for risk in women for overall NHL and various subtypes in relation to L&NC sweetened beverage and in some cases, aspartame intake. However, the biological significance of these findings is unclear and possibly due to chance (McCullough et al., 2014) . Based on the results of the analysis of this large prospective cohort of American adults, the investigators concluded that the intake of aspartame from the consumption of ≥1 L&NC-sweetened carbonated beverages per day was not associated with an increased risk of NHL or any of it subtypes (nor were sugar-sweetened beverages). McCullough et al. (2014) was one of the strongest studies available, although it was not reported if assessors were blinded to the status of the participants. All cohort studies identified met the majority of the NHLBI criteria.
Quality appraisal
Following review of the articles, it became apparent that the intake of diet drinks and/or packets of L&NC sweetener was being studied rather than the intake of aspartame. This is an immediate confounding factor as in addition to aspartame, other sugar substitutes that are used in diet beverages may include saccharin, cyclamate, acesulfame-K, sucralose, neotame, and stevia (Andreatta et al., 2008b) . However, with respect to the rating scheme, studies in which the authors clearly identified the fact that diet drinks were being assessed, met the criteria of clearly stating the objective.
The case-control study by Ewertz and Gill (1990) was not included in this phase since the L&NC sweeteners use was determined to be "mainly saccharin and cyclamate" rather than aspartame, and the study population was selected only 2 or 3 years after aspartame was first approved in the U.S.
The majority of the studies adequately reported their intended objective in the publication although data collected was initially multifaceted. Also, standard practices were generally followed to recruit suitable controls and the cohorts investigated are well established. Exposure criteria were deficient particularly for the case-control studies. For most studies, it was necessary to use diet beverages or packets of L&NC sweetener as a surrogate for aspartame, hence potential confounding by other L&NC sweeteners was prevalent. For many of the studies, the number of cases and controls remaining for the assessment of L&NC sweeteners was greatly reduced from the numbers originally recruited, specifically Hardell et al. (2001) and Andreatta et al. (2008a) . None of the case-control studies included a sample size justification.
The studies identified that assessed diet beverages, or L&NC sweeteners containing aspartame where it could reasonably assumed that aspartame exposure occurred, include eight case-control studies (Gurney et al., 1997; Hardell et al., 2001; Bunin et al., 2005; Gallus et al., 2007; Andreatta et al., 2008a; Bosetti et al., 2009; Chan et al., 2009; Cabaniols et al., 2011) and five prospective cohort (Schernhammer et al., 2005 (Schernhammer et al., , 2012 Lim et al., 2006a,b; Bao et al., 2008; McCullough et al., 2014) . Of these studies, two case-control studies (Bunin et al., 2005; Chan et al., 2009) and the five prospective studies were considered to have adequately demonstrated a clear research objective, acceptable recruitment of patients and controls in sufficient numbers, and managed a reasonable approximation of exposure to beverages known to include aspartame and analysis of the data compared to controls. For these seven studies, an answer of "yes" could be given for the majority of the NHLBI questions. The results of the seven studies are tabulated in Table 3 .
These reliable studies do not support that consumption of diet drinks or use of packets of L&NC sweeteners and, by association, aspartame, is associated with an increased risk of cancer in humans.
While the studies available may not have specifically limited exposures solely to aspartame, its common use in diet sodas, does allow for some assurance that the results obtained are generally applicable. Overall, there is little evidence to support an association between diet soda consumption or use of L&NC sweetener packets and risks of any types of cancers. The results from this study based on the NHLBI criteria are in general agreement with the findings of Bernardo et al. (2016) who used the Castle Ottawa Scale and Oxford classification. Thus, the original hypothesis of Olney et al. (1996) , linking aspartame use to brain cancer increases, can probably be ruled out.
Discussion and conclusions
The majority of the studies used diet beverages or packets/sachets of L& NC sweetener as the surrogate for aspartame. While there is some validity in this assumption, use of other types of sweeteners remain a confounder. It is noted that the per capita consumption of saccharin, which was introduced prior to aspartame, gradually increased from 5.5 pounds in 1970 until peaking at 10.0 pounds in 1984 (USDA, 1999) . Following introduction of aspartame in 1981, the per capita intake of aspartame gradually increased over time and in 1984, at the peak of saccharin consumption, the ratio of aspartame intake to saccharin intake was approximately 1.16:2. After 1984 until 1991, the intake of saccharin decreased while the intake of aspartame continued to rise in use; in 1991, the ratio of aspartame intake to saccharin was approximately 2.32:1. Thus, while aspartame use increased over the first 10 years that it was available, saccharin continued to be an alternative. Presently, there are even more alternatives available. However, for the studies considered in this assessment, the timeframe of exposure for the subjects studied would have coincided more closely to peak uses of aspartame.
Of the studies noted to be of reasonable quality, there was little evidence to support that exposures to diet beverages and L&NC sweeteners, and by extension aspartame, was associated with an increased risk of cancer in humans. While Schernhammer et al. (2012) considered their findings to "preserve" some possibility that aspartame and diet soda might show an effect on select cancers, based on a finding of NHL and multiple myeloma increased in men only, the authors also noted that the lack of findings in women alone, and for men and women combined, and a similarly elevated risk of NHL in men from consumption of regular soda did not rule out chance. Also, EFSA (2013) concluded that the study could be given little weight on the basis of the findings being limited to men, and also given that the relative risks Table 3 Summary of findings from epidemiology studies of that meet majority of NHLBI criteria.
were small, and there was a lack of a clear dose-response relationship. It is noted that Bernardo et al. (2016) also conducted a systematic review of studies that evaluated adverse effects in adult and child consumers of L&NC sweeteners, compared with individuals who were not consumers. For this assessment, Bernardo et al. (2016) chose the Castle Ottawa Scale and Oxford classification to critically evaluate the studies. In addition to cancer, other endpoints assessed included type 2 diabetes, infertility, and effects on pregnant women. From their analysis of the cancer studies, which included all of the same studies discussed in this assessment, they concluded that there was no association between aspartame consumption and increased risk of cancers of the brain, or hematopoietic, digestive, and reproductive systems, or between L&NC sweeteners consumption, in general, and the risk of cancers of the kidney or bladder.
The findings of the current work and the Bernardo et al. (2016) study are in agreement with the conclusions reached by the original FDA panel (based on animal studies at the time (U.S. FDA, 1981) and the findings of the European Food Safety Authority (EFSA, 2013) following their comprehensive evaluation of aspartame as a food additive that the epidemiology studies do not suggest an increased risk of the cancers examined with aspartame consumption.
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